Natco Pharma said the U.S. Patent and Trademark Office (PTO) has ruled in the favour of its marketing partner Mylan with regard to patent claims pertaining to multiple sclerosis drug Copaxone. The pa

Read more: http://www.thehindu.com/business/Industry/us-patent-office-rules-in-favour-of-mylan/article9032518.ece?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS_Syndication